{"entity":{"id":"del17p-tp53","kind":"term","name":"del(17p) / TP53 aberration in CLL","aka":[],"tldr":"A del(17p) deletion or TP53 mutation means loss or damage of the p53 safety gene in CLL. These patients should never get chemotherapy; they need BTK inhibitors or venetoclax, usually continuously.","summary":"Present in ~5-10% at diagnosis and up to 40% at relapse. Chemoimmunotherapy is ineffective; continuous BTK inhibition (SEQUOIA arm C, 5-year PFS 72% with zanubrutinib) or venetoclax-based therapy is standard; fixed-duration regimens have shorter remissions in this group. Excluded from AMPLIFY, so acalabrutinib-venetoclax is not labelled for del(17p)/TP53.","asOf":"2026-09-07","wikipedia":"https://en.wikipedia.org/wiki/Chronic_lymphocytic_leukemia","links":[{"label":"ClinicalTrials.gov NCT03336333: SEQUOIA","url":"https://clinicaltrials.gov/study/NCT03336333"},{"label":"ClinicalTrials.gov NCT03836261: AMPLIFY","url":"https://clinicaltrials.gov/study/NCT03836261"}],"tags":[],"related":[],"cancers":["cll"],"sections":[],"technologies":["cytogenetics-fish"],"targets":["tp53"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["sequoia","amplify"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"category":"Biomarkers"},"route":"/terms/del17p-tp53/","neighbours":{"cancer":[{"id":"cll","kind":"cancer","name":"Chronic lymphocytic leukaemia","route":"/cancers/cll/"},{"id":"cll-treatment-naive","kind":"cancer","name":"Chronic lymphocytic leukaemia, first treatment","route":"/cancers/cll-treatment-naive/"},{"id":"mantle-cell-lymphoma","kind":"cancer","name":"Mantle cell lymphoma","route":"/cancers/mantle-cell-lymphoma/"},{"id":"cll-relapsed","kind":"cancer","name":"Relapsed or refractory chronic lymphocytic leukaemia","route":"/cancers/cll-relapsed/"},{"id":"richter-transformation-cll","kind":"cancer","name":"Richter transformation of chronic lymphocytic leukaemia","route":"/cancers/richter-transformation-cll/"}],"technology":[{"id":"cytogenetics-fish","kind":"technology","name":"Cytogenetics and FISH","route":"/technologies/cytogenetics-fish/"}],"target":[{"id":"tp53","kind":"target","name":"TP53","route":"/targets/tp53/"}],"trial":[{"id":"amplify","kind":"trial","name":"AMPLIFY","route":"/trials/amplify/"},{"id":"sequoia","kind":"trial","name":"SEQUOIA","route":"/trials/sequoia/"}],"pairing":[{"id":"cit-in-del17p-caution","kind":"pairing","name":"Caution: chemoimmunotherapy in del(17p)/TP53 CLL","route":"/pairings/cit-in-del17p-caution/"}],"paper":[{"id":"paper-amplify-acalabrutinib-venetoclax-nejm-2025","kind":"paper","name":"AMPLIFY: fixed-duration acalabrutinib plus venetoclax, with or without obinutuzumab, versus chemo-immunotherapy in fit CLL patients","route":"/key-papers/paper-amplify-acalabrutinib-venetoclax-nejm-2025/"},{"id":"paper-cll14-venetoclax-obinutuzumab-nejm-2019","kind":"paper","name":"CLL14: one year of venetoclax plus obinutuzumab instead of chemo-immunotherapy in older, less fit CLL patients","route":"/key-papers/paper-cll14-venetoclax-obinutuzumab-nejm-2019/"},{"id":"paper-murano-venetoclax-rituximab-nejm-2018","kind":"paper","name":"MURANO: two years of venetoclax plus rituximab versus chemo-immunotherapy in relapsed CLL","route":"/key-papers/paper-murano-venetoclax-rituximab-nejm-2018/"}],"term":[{"id":"cll-ipi","kind":"term","name":"CLL-IPI (chronic lymphocytic leukaemia prognostic index)","route":"/terms/cll-ipi/"}],"pathway":[{"id":"p53-mdm2-axis","kind":"pathway","name":"The p53 network (guardian of the genome)","route":"/pathways/p53-mdm2-axis/"}],"biomarker":[{"id":"tp53-del17p","kind":"biomarker","name":"TP53 mutation and del(17p)","route":"/biomarkers/tp53-del17p/"}]}}